Lifang partners Dr. Wu Li and Dr. Yang Jian attended the 10th IP Forefront Pharma Forum in Shanghai from September 17-20, 2025, delivering keynote presentations on specialized intellectual property topics.

Dr. Wu presented on "Development and Evolution: The Pharmaceutical Patent Linkage System from an Innovative Drug Perspective," examining critical issues including the ineligibility of Type 3 Chemical Drugs under current regulations. He analyzed interpretations from the China National Intellectual Property Administration and Beijing Intellectual Property Court, exploring the system's applicability to different dosage forms and specifications, and concluded with proposed amendments and industry insights.

Dr. Yang addressed "Challenges and Strategies in Drafting Biopharma Patents: A Global Perspective," sharing practical experience in global portfolio management. She discussed key challenges in enablement, inventiveness, patent eligibility, and filing strategy, citing case studies from China, the U.S., and the EPO regarding sequence and indication claims. Dr. B also provided strategic recommendations for optimizing global patent applications while balancing efficiency and risk.

Additionally, Dr. Wu joined the panel "A Decade of Change in China’s Pharma IP: Past, Present, and Future," where experts debated unresolved issues in early patent dispute resolution, patent term compensation, and data protection systems, contributing ideas to advance system optimization and balance innovation with generic competition.